Results 221 to 230 of about 176,756 (350)

FOLFIRINOX vs. Gemcitabine/Nab‐Paclitaxel for Pancreatic Cancer by BRCA2 and TMB Status: A Japanese C‐CAT Database Study

Cancer Science, EarlyView.
In a large real‐world C‐CAT cohort of unresectable or recurrent pancreatic cancer, we evaluated outcomes with first‐line FOLFIRINOX versus gemcitabine/nab‐paclitaxel by BRCA2 pathogenic variant and TMB status. Survival was more strongly associated with therapeutic sequencing than the initial regimen, supporting early molecular profiling to optimize the
Kazuyuki Mizuno, Takuya Ishikawa, Takanori Ito, Yuko Takano, Osamu Maeda, Hiroki Kawashima, Yuichi Ando   +6 more
wiley   +1 more source

Age-Related Differences in Severe Adverse Events During Maintenance Therapy with PARP Inhibitors: A Retrospective Cohort Study in Japanese Patients with Ovarian Cancer. [PDF]

Target Oncol
Nishimyo K, Ishikawa KB, Aoki D, Fushimi K, Yamazaki T.   +4 more
europepmc   +1 more source

Latest clinical evidence and further development of PARP inhibitors in ovarian cancer [PDF]

, 2018
Mansoor Raza Mirza, Sandro Pignata, Jonathan A. Ledermann   +2 more
openalex   +1 more source

Requirements for PARP-1 covalent crosslinking to DNA (PARP-1 DPC)

DNA Repair, 2020
Rajendra, Prasad, Julie K, Horton, Samuel H, Wilson   +2 more
openaire   +2 more sources

SOD2‐Superoxide Metabolic Axis Regulates Mitophagy and Modulates TKIs Sensitivity in Head and Neck Squamous Cell Carcinoma

Cancer Science, EarlyView.
Our findings provide compelling evidence that the SOD2‐superoxide metabolic axis functions as a mitochondrial redox checkpoint that governs mitophagy and ultimately shapes TKI sensitivity. ABSTRACT Superoxide dismutase 2 (SOD2) has been implicated in head and neck squamous cell carcinoma (HNSCC), yet its mechanistic contribution in regulating tumor ...
Wan‐Hang Zhou, Shuo‐Jin Huang, An‐Xun Wang   +2 more
wiley   +1 more source

Lack of synergy between AR-targeted therapies and PARP inhibitors in homologous recombination-proficient prostate cancer. [PDF]

Proc Natl Acad Sci U S A
Traphagen NA, Wheeler E, Li R, Akhshi T, Ravindranathan R, Alfieri C, Lu F, Ahmed B, Tewari AK, Balk SP, Nelson PS, Corey E, Long H, D'Andrea AD, Qiu X, Brown M.   +15 more
europepmc   +1 more source

A novel glucose beta‐hydroxybutyrate combination improves hypoglycaemia recovery and patient‐reported outcomes in type 1 diabetes

Diabetes, Obesity and Metabolism, EarlyView.
Abstract Aims Hypoglycaemia remains a major barrier to optimal diabetes management. Current treatments based on simple sugars have limitations, including rapid glucose fluctuations and persistent neuroglycopenic symptoms. We investigated FLO23011, a novel multi‐substrate energy formulation containing glucose and beta‐hydroxybutyrate, as a superior ...
D. Russell‐Jones, V. Smout, S. Roy, G. Myers, R. Littlewood, F. Shojaee‐Moradie   +5 more
wiley   +1 more source

Targeted inhibition of PARP-1 in pulmonary epithelial cells and macrophages via SPA-functionalized microparticles attenuates sepsis-induced lung injury. [PDF]

Mater Today Bio
Xie X, Wu M, Geng Y, Bai J, Ma C, Yan Y, Liu Y, Lu L, Zhan L.   +8 more
europepmc   +1 more source

A Review of SIK2 in Ovarian Cancer: Function and Emerging Targeted Therapies. [PDF]

Onco Targets Ther
Xu Z, Gao X.
europepmc   +1 more source

The Stabilization Effect of Agmatine‐Salicylate Ionic Liquids on PARP‐1 for Parkinson's Disease: A Perspective from DFT and MD Simulations (Adv. Theory Simul. 12/2024) [PDF]

Sridhar Priyankha, Muthuramalingam Prakash   +1 more
openalex   +1 more source